CNS Drug Reviews

Changing Times at CNS Neuroscience & Therapeutics
pp. 1-1(1)

Redefining Affective Disorders: Relevance for Drug Development
pp. 2-9(8)
Authors: Targum, Steven D; Pollack, Mark H; Fava, Maurizio

Protection of Mouse Brain from Aluminum-induced Damage by Caffeic Acid
pp. 10-16(7)
Authors: Yang, Jun-Qing; Zhou, Qi-Xin; Liu, Bei-Zhong; He, Bai-Cheng

Ambroxol: A CNS Drug?
pp. 17-24(8)
Author: Weiser, Thomas

GABA_A Receptor Subtype-Selective Efficacy: TPA023, an α2/α3 Selective Non-sedating Anxiolytic and α5IA, an α5 Selective Cognition Enhancer
pp. 25-35(11)
Author: Atack, John R.

Ascomycin and FK506: Pharmacology and Therapeutic Potential as Anticonvulsants and Neuroprotectants
pp. 36-46(11)
Authors: Sierra-Paredes, Germán; Sierra-Marcuño, Germán

PE2I: A Radiopharmaceutical for In vivo Exploration of the Dopamine Transporter
pp. 47-64(18)
Authors: Emond, Patrick; Guilloteau, Denis; Chalon, Sylvie

Preclinical Characterization of A-582941: A Novel α7 Neuronal Nicotinic Receptor Agonist with Broad Spectrum Cognition-Enhancing Properties
pp. 65-82(18)
Authors: Tietje, Karin R.; Anderson, David J.; Bitner, R. Scott; Blomme, Eric A.; Brackemeyer, Paul J.; Briggs, Clark A.; Browman, Kaitlin E.; Bury, Dagmar; Curzon, Peter; Drescher, Karla U.; Frost, Jennifer M.; Fryer, Ryan M.; Fox, Gerard B.; Gronlien, Jens Halvard; Håkerud, Monika; Gubbins, Earl J.; Halm, Sabine; Harris, Richard; Helfrich, Rosalind J.; Kohlhaas, Kathy L.; Law, Devalina; Malysz, John; Marsh, Kennan C.; Martin, Ruth L.; Meyer, Michael D.; Molesky, Angela L.; Nikkel, Arthur L.; Otte, Stephani; Pan, Liping; Puttfarcken, Pamela S.; Radek, Richard J.; Robb, Holly M.; Spies, Eva; Thorin-Hagene, Kirsten; Waring, Jeffrey F.; Ween, Hilde; Xu, Hongyu; Gopalakrishnan, Murali; Bunnelle, William H.

Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease
pp. 83-93(11)
Author: Lees, Andrew J.